Gain Therapeutics, Inc. SEC filings GANX
Gain Therapeutics, Inc. has 240 filings in SEC EDGAR's recent list, going back to Jul 30, 2020. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 4 | Insider transaction | Oct 30, 2026 | Oct 29, 2026 |
| 3 | Initial insider ownership | Oct 30, 2026 | Oct 28, 2026 |
| 4 | Insider transaction | Jul 17, 2026 | Jul 15, 2026 |
| 4 | Insider transaction | Jul 17, 2026 | Jul 15, 2026 |
| 4 | Insider transaction | Jul 17, 2026 | Jul 15, 2026 |
| 4 | Insider transaction | Jul 17, 2026 | Jul 15, 2026 |
| 4 | Insider transaction | Jul 17, 2026 | Jul 15, 2026 |
| 4 | Insider transaction | Jul 17, 2026 | Jul 15, 2026 |
| 4 | Insider transaction | Mar 26, 2026 | Mar 24, 2026 |
| 4 | Insider transaction | Mar 26, 2026 | Mar 24, 2026 |
| 4 | Insider transaction | Jun 25, 2025 | Jun 24, 2025 |
| 4 | Insider transaction | Jun 25, 2025 | Jun 24, 2025 |
| 4 | Insider transaction | Jun 25, 2025 | Jun 24, 2025 |
| 4 | Insider transaction | Jun 25, 2025 | Jun 24, 2025 |
| 4 | Insider transaction | Jun 25, 2025 | Jun 24, 2025 |
| 4 | Insider transaction | Jun 25, 2025 | Jun 24, 2025 |
| 4 | Insider transaction | Jun 25, 2025 | Jun 24, 2025 |
| 4 | Insider transaction | Mar 21, 2025 | Mar 20, 2025 |
| 4 | Insider transaction | Mar 21, 2025 | Mar 20, 2025 |
| 4 | Insider transaction | Jan 7, 2025 | Jan 6, 2025 |
| 4 | Insider transaction | Aug 12, 2024 | Aug 9, 2024 |
| 4 | Insider transaction | Aug 12, 2024 | Aug 9, 2024 |
| 4 | Insider transaction | Jul 1, 2024 | Jul 1, 2024 |
| 4 | Insider transaction | Jun 26, 2024 | Jun 24, 2024 |
| 4 | Insider transaction | Jun 26, 2024 | Jun 24, 2024 |
| 4 | Insider transaction | Jun 26, 2024 | Jun 24, 2024 |
| 4 | Insider transaction | Jun 26, 2024 | Jun 24, 2024 |
| 4 | Insider transaction | Jun 26, 2024 | Jun 24, 2024 |
| 4 | Insider transaction | Jun 26, 2024 | Jun 24, 2024 |
| 4 | Insider transaction | Jun 26, 2024 | Jun 24, 2024 |
| 4 | Insider transaction | Apr 8, 2024 | Apr 8, 2024 |
| 3 | Initial insider ownership | Apr 8, 2024 | Apr 5, 2024 |
| 4 | Insider transaction | Apr 1, 2024 | Mar 28, 2024 |
| 4 | Insider transaction | Mar 28, 2024 | Mar 26, 2024 |
| 4 | Insider transaction | Mar 25, 2024 | Mar 21, 2024 |
| 4 | Insider transaction | Mar 25, 2024 | Mar 21, 2024 |
| 4 | Insider transaction | Dec 22, 2023 | Dec 20, 2023 |
| 4 | Insider transaction | Dec 14, 2023 | Dec 7, 2023 |
| 4 | Insider transaction | Oct 3, 2023 | Oct 1, 2023 |
| 4 | Insider transaction | Sep 22, 2023 | Sep 20, 2023 |
| 4 | Insider transaction | Sep 22, 2023 | Sep 20, 2023 |
| 4 | Insider transaction | Jul 5, 2023 | Jul 1, 2023 |
| 4 | Insider transaction | Jun 26, 2023 | Jun 23, 2023 |
| 4 | Insider transaction | Jun 26, 2023 | Jun 23, 2023 |
| 4 | Insider transaction | Jun 26, 2023 | Jun 23, 2023 |
| 4 | Insider transaction | Jun 26, 2023 | Jun 23, 2023 |
| 4 | Insider transaction | Jun 26, 2023 | Jun 23, 2023 |
| 4 | Insider transaction | Jun 26, 2023 | Jun 23, 2023 |
| 4 | Insider transaction | Apr 12, 2023 | Apr 10, 2023 |
| 3 | Initial insider ownership | Apr 12, 2023 | Apr 10, 2023 |
| 4 | Insider transaction | Mar 27, 2023 | Mar 23, 2023 |
| 4 | Insider transaction | Mar 27, 2023 | Mar 23, 2023 |
| 4 | Insider transaction | Mar 27, 2023 | Mar 23, 2023 |
| 3 | Initial insider ownership | Dec 21, 2022 | Dec 12, 2022 |
| 4 | Insider transaction | Sep 22, 2022 | Sep 20, 2022 |
| 4 | Insider transaction | Sep 22, 2022 | Sep 20, 2022 |
| 4 | Insider transaction | Sep 22, 2022 | Sep 20, 2022 |
| 4 | Insider transaction | Sep 22, 2022 | Sep 20, 2022 |
| 4 | Insider transaction | Sep 22, 2022 | Sep 20, 2022 |
| 4 | Insider transaction | Sep 22, 2022 | Sep 20, 2022 |
| 4 | Insider transaction | Sep 22, 2022 | Sep 20, 2022 |
| 4 | Insider transaction | Sep 22, 2022 | Sep 20, 2022 |
| 4 | Insider transaction | Jul 19, 2022 | Jul 15, 2022 |
| 4 | Insider transaction | Jul 19, 2022 | Jul 15, 2022 |
| 4 | Insider transaction | May 27, 2022 | May 25, 2022 |
| 4 | Insider transaction | May 23, 2022 | May 19, 2022 |
| 4/A | Filing | May 23, 2022 | May 19, 2022 |
| 4 | Insider transaction | May 19, 2022 | May 19, 2022 |
| 4/A | Form 4/a submission | Apr 21, 2022 | Aug 16, 2021 |
| 3/A | Form 3/a submission | Apr 21, 2022 | Mar 17, 2021 |
| 4 | Insider transaction | Dec 28, 2021 | Dec 23, 2021 |
| 3 | Initial insider ownership | Dec 28, 2021 | Dec 23, 2021 |
| 4 | Insider transaction | Aug 17, 2021 | Aug 16, 2021 |
| 3 | Initial insider ownership | Mar 29, 2021 | Mar 17, 2021 |
| 3 | Initial insider ownership | Mar 29, 2021 | Mar 17, 2021 |
| 3 | Initial insider ownership | Mar 29, 2021 | Mar 17, 2021 |
| 3 | Initial insider ownership | Mar 29, 2021 | Mar 17, 2021 |
| SC 13G/A | Amended ownership over 5% (passive) | Mar 29, 2021 | — |
| 3 | Initial insider ownership | Mar 17, 2021 | Mar 17, 2021 |
| 3 | Initial insider ownership | Mar 17, 2021 | Mar 17, 2021 |
| 3 | Initial insider ownership | Mar 17, 2021 | Mar 17, 2021 |
| 3 | Initial insider ownership | Mar 17, 2021 | Mar 17, 2021 |
| 3 | Initial insider ownership | Mar 17, 2021 | Mar 17, 2021 |
Showing 83 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GANX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bethesda, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1819411
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.